var data={"title":"Interferon gamma-1b: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Interferon gamma-1b: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6381?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=interferon-gamma-1b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Interferon gamma-1b: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183604\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Actimmune</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183622\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Interferon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183607\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing expressed in mcg; 50 mcg is equivalent to 1 million units (50 mcg/m<sup>2</sup> is equivalent to 1 million units/m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic granulomatous disease:</b> SubQ: 50 mcg/m<sup>2</sup> (1 million units/m<sup>2</sup>) 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant osteopetrosis (severe):</b> SubQ: 50 mcg/m<sup>2</sup> (1 million units/m<sup>2</sup>) 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183617\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing expressed in mcg; 50 mcg is equivalent to 1 million units (50 mcg/m<sup>2</sup> is equivalent to 1 million units/m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic granulomatous disease:</b> Children and Adolescents: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body surface area (BSA) &le;0.5 m<sup>2</sup>: 1.5 mcg/kg/dose 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &gt;0.5 m<sup>2</sup>: 50 mcg/m<sup>2</sup> (1 million units/m<sup>2</sup>) 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant osteopetrosis (severe):</b> Infants, Children, and Adolescents: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body surface area (BSA) &le;0.5 m<sup>2</sup>: 1.5 mcg/kg/dose 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &gt;0.5 m<sup>2</sup>: 50 mcg/m<sup>2</sup> (1 million units/m<sup>2</sup>) 3 times weekly; maximum dose: 50 mcg/m<sup>2</sup></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183608\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962238\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; drug accumulation may occur in patients with severe renal insufficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962239\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; drug accumulation may occur in patients with advanced hepatic disease. If severe transaminase elevations occur during treatment, interrupt and reduce the dose upon resolution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934668\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">If severe reactions occur, reduce dose by 50% or therapy should be interrupted until adverse reaction abates.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183588\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actimmune: 2,000,000 units/0.5 mL (0.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183575\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28842879\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Actimmune Injection, solution: 100 mcg (2 million units) per 0.5 mL (50 mcg is equivalent to 1 million units)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4419053\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer by SubQ injection into the right and left deltoid or anterior thigh. Consider premedication with acetaminophen and/or bedtime administration to minimize adverse reactions (eg, flu-like symptoms). Do not mix with other drugs in the same syringe.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183589\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic granulomatous disease:</b> Reduction in the frequency and severity of serious infections associated with chronic granulomatous disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant osteopetrosis (severe): </b> To delay time to disease progression in patients with severe, malignant osteopetrosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183581\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Based on 50 mcg/m<sup>2</sup> dose administered 3 times weekly for chronic granulomatous disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fever (52%), headache (33%), chills (14%), fatigue (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Rash (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (14%), vomiting (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site erythema or tenderness (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (10%), abdominal pain (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (6%), arthralgia (2%), back pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Alkaline phosphatase elevated, atopic dermatitis, granulomatous colitis, hepatomegaly, hypersensitivity reactions, hypokalemia, neutropenia, Stevens-Johnson syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Additional adverse reactions noted at doses &gt;100 mcg/m<sup>2</sup> administered 3 times weekly: ALT increased, AST increased, autoantibodies increased, bronchospasm, chest discomfort, confusion, dermatomyositis exacerbation, disorientation, DVT, gait disturbance, GI bleeding, hallucinations, heart block, heart failure, hepatic insufficiency, hyperglycemia, hypertriglyceridemia, hyponatremia, hypotension, interstitial pneumonitis, lupus-like syndrome, MI, neutropenia, pancreatitis (may be fatal), Parkinsonian symptoms, PE, proteinuria, renal insufficiency (reversible), seizure, syncope, tachyarrhythmia, tachypnea, thrombocytopenia, TIA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183593\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to interferon gamma, <i>E. coli</i> derived products, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183578\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Dose-related reversible neutropenia and thrombocytopenia (may be severe) have been reported; use caution in patients with myelosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Neurologic disorders (ie, decreased mental status, gait disturbances, dizziness) have been noted at the higher doses (&gt;250 mcg/m<sup>2</sup>/day); most of these abnormalities were reversible within a few days after dose reduction or discontinuation. Use with caution in patients with a history of seizure disorder or compromised CNS function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flu-like symptoms: Acute and transient flu-like symptoms (eg, fever, headache, chills, myalgia, fatigue) have been noted at the higher doses (&gt;250 mcg/m<sup>2</sup>/day) and may exacerbate preexisting cardiovascular disorders; some of the flu-like symptoms may be minimized by bedtime administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Elevations of AST and/or ALT (up to 25-fold) have been observed and were reversible with dose reduction or interruption of treatment. Incidence may be increased in children &lt;1 year; perform monthly liver function assessments in this age group; modify dosage if severe elevations of liver enzyme develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Acute serious hypersensitivity reactions have been reported (case reports); transient cutaneous rashes may occur; treatment interruption may be necessary. Discontinue therapy immediately if an acute reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with preexisting cardiovascular disease, including ischemia, heart failure, or arrhythmia. In a scientific statement from the American Heart Association, interferon has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic function impairment: Drug accumulation may occur in patients with advanced hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal function impairment: Drug accumulation may occur in patients with severe renal insufficiency; renal toxicity has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The vial stopper may contain dry natural rubber and may cause allergic reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183618\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183582\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8987&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183594\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183595\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if interferon gamma 1b is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183586\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelets, LFTs (monthly in children &lt;1 year), electrolytes, BUN, creatinine, and urinalysis prior to therapy and at 3-month intervals</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4418991\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferon gamma participates in immunoregulation by enhancing the oxidative metabolism of macrophages; it also enhances antibody dependent cellular cytotoxicity, activates natural killer cells and has a role in the expression of Fc receptors and major histocompatibility antigens.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183592\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM, SubQ: &gt;89%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IM: ~3 hours, SubQ: ~6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: IM: ~4 hours (1.5 ng/mL); SubQ: ~7 hours (0.6 ng/mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323199\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Actimmune Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000000 units/0.5 mL (0.5 mL): $5,232.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183596\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Gama (CN);</li>\n      <li>Immukine (BE, LU, NL);</li>\n      <li>Imufor (AR, AT);</li>\n      <li>Imukin (AE, AT, AU, BH, CH, CO, CY, CZ, DE, DK, EG, ES, FI, FR, GB, GR, HU, IL, IQ, IR, IT, JO, KW, LB, LY, NO, OM, PL, PT, QA, SA, SE, SG, SY, TW, YE);</li>\n      <li>Imukin Inj. (NZ);</li>\n      <li>Intermax gamma (KR);</li>\n      <li>Lizhu Yindefu (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Actimmune solution for injection (interferon gamma-1b) [prescribing information]. Lake Forest, IL: HZNP USA; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Key LL, Rodriguiz RM, Willi SM, et al, &ldquo;Long-Term Treatment of Osteopetrosis With Recombinant Human Interferon Gamma,&rdquo; <i>N Engl J Med</i> 1995, 332(24):1594-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-gamma-1b-drug-information/abstract-text/7753137/pubmed\" target=\"_blank\" id=\"7753137\">7753137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marciano BE, Wesley R, DeCarlo E, et al, &ldquo;Long-Term Interferon-Gamma Therapy for Patients With Chronic Granulomatous Disease,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(5):692-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-gamma-1b-drug-information/abstract-text/15356785/pubmed\" target=\"_blank\" id=\"15356785\">15356785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/interferon-gamma-1b-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8987 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183604\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183622\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F183607\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F183617\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F183608\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15962238\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962239\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F2934668\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183588\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183575\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F28842879\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F4419053\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183589\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F183581\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183593\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F183578\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F183618\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F183582\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183594\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F183595\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F183586\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4418991\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F183592\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323199\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F183596\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8987|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=interferon-gamma-1b-patient-drug-information\" class=\"drug drug_patient\">Interferon gamma-1b: Patient drug information</a></li></ul></div></div>","javascript":null}